| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2018 | AMRN Amarin Corp Plc\uk | Kalb Michael Wayne | SVP And CFO | Sell | 150,000 | $10.42 | $1,562,750.82 | -60.0% | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Hicks Michael-Bryant | See Remarks | Buy | 5,000 | $24.00 | $120,000.00 | New | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Anand Kapila K | Director | Buy | 1,200 | $24.00 | $28,800.00 | New | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Cabral Ramiro Martin | See Remarks | Buy | 1,000 | $24.00 | $24,000.00 | New | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Lin Sarena S | See Remarks | Buy | 20,000 | $24.00 | $480,000.00 | New | |
| Sep 24, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 1,079,706 | $10.56 | $11,400,975.47 | -52.2% | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Schacht Aaron L | See Remarks | Buy | 400 | $24.00 | $9,600.00 | New | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Kurzius Lawrence Erik77 | Director | Buy | 10,000 | $24.00 | $240,000.00 | New | |
| Sep 21, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $6.63 | $1,219,000.00 | -0.5% | |
| Sep 18, 2018 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 1,241 | $23.71 | $29,420.39 | -47.2% | |
| Sep 18, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 2,488 | $23.69 | $58,943.21 | -100% | |
| Sep 18, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, Growth Markets Commercial | Sell | 1,379 | $23.69 | $32,669.89 | -16.4% | |
| Sep 18, 2018 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 279,851 | $70.08 | $19,611,818.15 | -28.8% | |
| Sep 18, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 625 | $23.71 | $14,816.88 | -7.9% | |
| Sep 18, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 2,376 | $23.71 | $56,327.83 | -100% | |
| Sep 18, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 6,870 | $14.56 | $100,027.20 | -0.2% | |
| Sep 18, 2018 | LLY Eli Lilly & Co | Zulueta Alfonso G | SVP &President, Lilly Int'l | Sell | 6,000 | $106.31 | $637,830.00 | -5.3% | |
| Sep 17, 2018 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 107,360 | $70.18 | $7,534,290.82 | -66.0% | |
| Sep 17, 2018 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | CEO | Sell | 29,539 | $65.00 | $1,920,035.00 | -8.1% | |
| Sep 17, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 15,874 | $14.58 | $231,442.92 | -0.2% | |
| Sep 14, 2018 | BHC Bausch Health Companies Inc. | Herendeen Paul | EVP And CFO | Buy | 10,000 | $22.61 | $226,100.00 | +4.8% | |
| Sep 14, 2018 | BHC Bausch Health Companies Inc. | Papa Joseph C | Chairman &CEO | Buy | 30,000 | $22.32 | $669,600.00 | +4.8% | |
| Sep 13, 2018 | BHC Bausch Health Companies Inc. | De Schutter Richard U | Director | Buy | 125,000 | $23.96 | $2,995,000.00 | +92.8% | |
| Sep 13, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 30,959 | $14.49 | $448,462.97 | -0.4% | |
| Sep 13, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $6.30 | $1,151,640.00 | -1.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.